Gale Smith, Ph.D.
Vice President of Vaccine Development

Gale Smith, Ph.D. Dr. Smith is a leader in vaccine technology and holds numerous patents for the baculovirus-insect cell expression system, influenza vaccines and adjuvants. At Novavax, Dr. Smith has developed the first known commercial, scalable process for the manufacture of virus-like particle vaccines for influenza. He also has collaborated with the U.S. Centers for Disease Control and Prevention in testing a virus-like particle vaccine to protect animals against the H9N2 influenza. Prior to joining Novavax, Dr. Smith led a team at Protein Sciences Corp. that developed the first experimental vaccine for HIV approved by the U.S. Food and Drug Administration for testing in the United States. Dr. Smith also collaborated with the National Institute of Allergy and Infectious Diseases and the National Institute of Health to produce the first experimental vaccine tested in man against the H5N1 avian influenza. Dr. Smith did graduate work at the Baylor College of Medicine and has a Ph.D. in Microbiology from Texas A&M University.